After hours: February 7 at 6:57:37 PM EST Loading Chart for AKYA ...

Goldman Sachs analyst Matthew Sykes double downgraded Cytek Biosciences (CTKB) to Sell from Buy with a price target of $4.50, down from $7. The ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

A new BD will have four new operating segments: medical essentials, connected care, BioPharma systems and interventional.

Roche Holding AG Akt-0.45% CHF234.65B ...

Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences. BTIG 12th Annual MedTech, ...

Activist Starboard took a position in Becton Dickinson, calling for the company to sell its life sciences business. The ...

To develop a low-cost, instrument and battery free rapid point of care test platform to detect infectious diseases in low- and middle-income countries ...